<DOC>
	<DOCNO>NCT01851850</DOCNO>
	<brief_summary>The purpose study extend use opicapone 25 50mg per day subject participate BIA 9-1067-302 clinical trial accord form 4a additional three year .</brief_summary>
	<brief_title>Continuation Treatment Protocol Patient Who Participated BIA 9-1067-302 Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>clinical diagnosis PD subject willing participate trial . subject participate BIA 91067302 clinical trial . subject n't take part BIA 91067302 clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>PD</keyword>
	<keyword>Off period</keyword>
	<keyword>quality life</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>end-off-dose motor fluctuation</keyword>
</DOC>